Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

Author:

Ebrahimi Neda1,Herbstritt Sandra2,Gold Ralph2,Amezcua Lilyana3,Koren Gideon1,Hellwig Kerstin2

Affiliation:

1. Motherisk Program, Division of Pharmacology and Toxicology, The Hospital for Sick Children, Canada/University of Toronto, Leslie Dan Faculty of Pharmacy, Canada

2. St. Josef Hospital, Faculty of Medicine, Ruhr University, Germany

3. MS Comprehensive Care Center USC, Keck School of Medicine, USA

Abstract

Background: Safety data on first-trimester natalizumab exposure are scarce, as natalizumab is usually withdrawn three months before pregnancy. Objective: The objective of this paper is to investigate the fetal safety of exposure to natalizumab (Tysabri®) during the first trimester of pregnancy using disease-matched (DM) and healthy control (HC) comparison groups. Methods: A total of 101 German women with RRMS exposed to natalizumab during the first trimester of pregnancy were identified. Birth outcomes in the exposed group were compared to a DM group ( N = 78) with or without exposure to other disease-modifying drugs, and an HC group ( N = 97). Results: A total of 77, 69 and 92 live births occurred in the Exposed, DM and HC groups, respectively. The rates of major malformations ( p = 0.67), low birth weight (<2500 grams) ( p = 1.0) and premature birth ( p = 0.37) did not differ among groups. Higher miscarriage rates ( p = 0.002) and lower birth weights ( p = 0.001) occurred among the Exposed and DM groups, as compared to the HC; however, there was no significant difference between the Exposed and DM groups. Conclusion: Exposure to natalizumab in early pregnancy does not appear to increase the risk of adverse pregnancy outcomes in comparison to a DM group not exposed to natalizumab.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Cited by 105 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3